transMedChem offers Drug Discovery Consulting and operational execution of
Project Management in all phases of preclinical R&D:
With over 30 years of senior-level experience in drug discovery, transMedChem offers deep medicinal chemistry expertise supported by a strong foundation in organic synthesis. This spans a wide range of therapeutic areas, target families and pathways, and sophisticated medicinal chemistry strategies, with a proven track record of advancing compounds from hit to lead to clinical stage.
Sennhenn P., Meier-Ewert S., Khandelwal N.
A 5-Thiazolecarboxamide kinase inhibitor and uses thereof
US 12139480
Conrad M., Nakamura T., Proneth B., Sennhenn P.
3-Phenylquinazolinones as novel anti-cancer therapy
WO 2024 115673
Sennhenn P., Oumouch S., Andreux P.
Urolithin derivatives and therapeutic uses thereof
US 2024 0051933
Sheltzer J., Sennhenn P., Chuaqui C.
Compounds targeting CDK11 and methods of using the same
WO 2024 097228
Menzer W., Knobloch G., Lieleg C., Schomburg A., Ladurner A., Sennhenn P.
ALC1 inhibitors and synergy with PARPi
US 2024 0033363
Celanire S., Dos Santos Carvalho J., Rombouts F., Sennhenn P., Curcio M., Reis Pedro J.
Compounds and use thereof as HDAC6 inhibitors
WO 2023 118507
Menzer W., Knobloch G., Schomburg A., Lieleg C., Sennhenn P.
Viral Combination Therapy
WO 2023 161427
Sennhenn P., Loferer H., Bancroft D., Kluge A.
Bicyclic kinase inhibitors and uses thereof
US 2023 0192701
Rinsch C., Andreux P., Sutton J., Seward E., Knight J., Linney I., Sennhenn P., Oumouch S., Beaufils F., Fessard T.
Urolithin derivatives and methods of use thereof
US 11820751
Menzer W., Knobloch G., Schomburg A., Lielig C., Sennhenn P.
Inhibitors of viral helicases binding to a novel allosteric site
WO 2023 073222
Menzer W., Sahiri K., Knobloch G., Schomburg A., Ladurner A., Sennhenn P.
Use of ALC1 inhibitors and synergy with PARPi
WO 2023 213833
Sennhenn P., Bissinger S., Loferer H., Bancroft D., Michels T., Khandelwal N.
Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
US 2023 0348453
Rinsch, C. Andreux, P., Sutton J., Seward E., Knight J., Linney I., Sennhenn P.
Urolithin derivatives and methods of use thereof
WO 2022 162471
Hasleton M., Sennhenn P.
Plasmalogen derivatives and uses thereof
WO 2022 263927
Sennhenn P., Bissinger S., Loferer H., Bancroft D., Michels T., Khandelwal N.
Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
IL297481A
Menzer W., Knobloch G., Lieleg C., Schomburg A., Ladurner A., Sennhenn P.
ALC1 inhibitors and synergy with PARPi
WO 2022 117782
Menzer W., Knobloch G., Lieleg C., Schomburg A., Ladurner A., Sennhenn P.
Method to evaluate the capability of compounds on the trapping of proteins
EP 2021 1716.4
Sennhenn P., Meier-Ewert S., Khandelwal N., Bancroft D.
Heterocyclic kinase inhibitors and uses thereof
WO 2021 0387982
Sennhenn P., Bissinger S., Loferer H., Bancroft D., Michels T., Khandelwal N.
Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
WO 2021 214117
Sennhenn P., Loferer H., Bancroft D., Kluge A.
Bicyclic kinase inhibitors and uses thereof
WO 2021 219731
Sennhenn P., Meier-Ewert S., Khandelwal N., Bancroft D.
Heterocyclic kinase inhibitors and uses thereof for treatment of proliferative disorders
WO 2020 083926
Sennhenn P., Meier-Ewert S., Khandelwal N.
Dasatinib and other protein kinase inhibitors and methods of preparation and uses thereof for treating proliferative disorders such as cancer
WO 2020 083909
Sennhenn P., Meier-Ewert S., Khandelwal N., Bancroft D.
Heterocyclic kinase inhibitors and uses thereof
EP 3643713
Sorrentino A., Beckhove, P., Michels T., Khandelwal N., Boutros M., Breinig M., Sennhenn P., Meier-Ewert S.
Intracellular kinase associated with resistance against anti-tumor immune responses and uses thereof for treating proliferative disorders such as cancer
WO 2018193084
Conrad M., Schick J., Proneth B., Sennhenn P.
Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death
WO 2016 075137
Conrad M., Schick J., Proneth B., Sennhenn P.
Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
WO 2015 007730
Brandstetter T., Eickhoff J., Koestler R., Schoop A., Sennhenn P., Becker F., Kauffmann C.
Dihydropteridinones as PLK Inhibitors.
WO 2009 130016
Brandstetter T., Eickhoff J., Koestler R., Schoop A., Sennhenn P., Becker F., Kauffmann C.
PLK Inhibitor
EP2325185
Sennhenn P., Hafenbradl D., Brandstetter T., Henry C., Woodcock T., Koestler R., Schoop A., Vogt J., Walch H., Backes A., Baumann M., Zybarth G., Mueller G.
Novel 5-sulphonylamino-benzothiophenes as anti-cancer agents.
EP10157556
Henry C., Sennhenn P., Woodcock T., Schoop A.
Novel 5-acylamino-benzothiophenes as anti-cancer agents.
EP 10157558
Reiser U., Kraemer O., Sennhenn P., Spevak W.
Spiro- (THO) benzopyran-2, 4’-piperidine- and cyclohexane derivatives as inhibitors of specific cell cycle enzymes.
WO 2007 128782
Reiser U., Ettmayer P., Kraemer O., Sennhenn P., Spevak W.
New chemical compounds
WO 2007 144370
Sennhenn P., Mantoulidis A., Treu M., Tontsch-Grunt U., Spevak W., McConnel D., Schoop A., Brueckner R., Jacobi A., Guertler U., Schnapp G., Klein C. Himmelsbach F., Pautsch A., Betzemeier B., Herfurth L., Mack J., Wiedenmayer D., Bader G., Reiser U.
Alpha-Carbolines as CDK-1 Inhibitors.
WO 2006 131552
Keith S. Robinson, Peter Sennhenn, Daniel S. Yuan, Hai Liu, David Taddei and Wei Luo
TMBIM6/BI-1 is an intracellular environmental regulator that induces paraptosis in cancer via ROS and Calcium-activated ERAD II pathways
Oncogene, 2024 – https://doi.org/10.1038/s41388-024-03222-x
Toshitaka Nakamura, Eikan Mishima, André Santos Dias Mourão, Dietrich Trümbach, Sebastian Doll, Peter Sennhenn, Jonas Wanninger, Elena Lytton, José Pedro Friedmann Angeli, Michael Sattler, Bettina Proneth and Marcus Conrad
Integrated chemical-genetic screens unveil FSP1 mechanisms and ferroptosis vulnerabilities
Nat Struct Mol Biol, 2023, 30, 1806
Eikan Mishima, Toshitaka Nakamura, Jiashuo Zheng, Weijia Zhang, André Santos Dias Mourão, Peter Sennhenn, Marcus Conrad
DHODH inhibitors sensitize cancer cells to ferroptosis via FSP1 inhibition
Nature, 2023, 619 (7968), E9–E18
Akito Koike, Frank Becker, Peter Sennhenn, Jason Kim, Jenny Zhang, Stefan Hannus, Klaus Brehm
Targeting Echinococcus multilocularis PIM kinase for improving anti-parasitic chemotherapy
PLoS Negl Trop Dis, 2022, 16(10)
Akito Koike, Katia Cailliau, Jerome Vicogne, Frank Becker, Peter Sennhenn, Colette Dissous, Stefan Hannus, Klaus Brehm
In vitro screening of kinase inhibitors on Echinococcus multilocularis
29th annual meeting of German Society for Parasitology, Bonn, March 15–17, 2021
Tillmann Michels, Antonio Sorrentino, Ayse Nur Menevse, Stefan Bissinger, Peter Sennhenn, Valentina Volpin, Sabrina Genssler Hannes Loferer, Christian Kohler, Rainer Spang, Michael Rheli, Christian Schmidl, Marco Breinig, Michael Boutros, Sebastian Meier-Ewert, Apollon Papadimitriou, Philipp Beckhove and Nisit Khandelwal
Salt-inducible kinase 3 facilitates tumor cell resistance against cytotoxic T cell attack by shifting TNF signaling from apoptosis to survival.
AACR Virtual Annual Meeting, 2020
Trebosc V., Gartenmann S., Royet K., Manfredi P., Tötzl M., Schellhorn B., Pieren M., Tigges M., Lociuro S., Sennhenn P., Gitzinger M., Bumann D., Kemmer C.
A novel genome editing platform for drug resistant Acinetobacter baumannii revealed an AdeR-unrelated tigecycline resistance mechanism.
Antimicrobial Agents and Chemotherapy, 2016, 60, 7263–7271
Schellhorn B., Kemmer C., Lucchini V., Gartenmann S., Trebosc V., Deroose F., Sennhenn P., Lociuro S., Tigges M., Gitzinger M., Pieren M.
Identification of VanR inhibitors re-sensitising vancomycin-resistant enterococci (VRE) towards glycopeptide antibiotics.
26th ECCMID Congress, Amsterdam, Netherlands, April 9–12, 2016
Conrad M., Schick J., Proneth B., Sennhenn P.
Tissue protection by non-apoptotic cell death inhibitors.
BioVaria, München, Germany, May 11, 2015
Chellat M., Raguz L., Sephton M., Züger P., Brand M., Schneider P., Tigges M., Gitzinger M., Sennhenn P., Pieren M., Levi A., Schellhorn B., Gygaxc D., Spiesc P., Riedl R.
Tackling Antibiotic Resistance by Transcription Repressor Inhibitory Compounds
Molecules for the Life Sciences, Swiss Chemical Society ILMAC-FH-Award 2013
Backes A., Sennhenn P., Müller G.
Design principles of kinase inhibitors.
In Protein Kinase Targets; Eds. Müller G., Klebl B.; VCH-Wiley: Weinheim, Germany, 2011
Müller G., Sennhenn P., Woodcock T., Neumann L.
The retro-design concept for novel kinase inhibitors.
IDrugs, 2010, 13, 457–466
Sennhenn P., Woodcock T., Müller G., Neumann L.
Novel Generation Kinase Inhibitors: Deep Pocket Binders by Fragment-Based Design
Frontiers in Medicinal Chemistry, Barcelona, Spain, 2009
Keith S. Robinson, Peter Sennhenn, Daniel S. Yuan, Hai Liu, David Taddei and Wei Luo
TMBIM6/BI-1 is an intracellular environmental regulator that induces paraptosis in cancer via ROS and Calcium-activated ERAD II pathways
Oncogene, 2024 – https://doi.org/10.1038/s41388-024-03222-x
Toshitaka Nakamura, Eikan Mishima, André Santos Dias Mourão, Dietrich Trümbach, Sebastian Doll, Peter Sennhenn, Jonas Wanninger, Elena Lytton, José Pedro Friedmann Angeli, Michael Sattler, Bettina Proneth and Marcus Conrad
Integrated chemical-genetic screens unveil FSP1 mechanisms and ferroptosis vulnerabilities
Nat Struct Mol Biol, 2023, 30, 1806
Eikan Mishima, Toshitaka Nakamura, Jiashuo Zheng, Weijia Zhang, André Santos Dias Mourão, Peter Sennhenn, Marcus Conrad
DHODH inhibitors sensitize cancer cells to ferroptosis via FSP1 inhibition
Nature, 2023, 619 (7968), E9–E18
Akito Koike, Frank Becker, Peter Sennhenn, Jason Kim, Jenny Zhang, Stefan Hannus, Klaus Brehm
Targeting Echinococcus multilocularis PIM kinase for improving anti-parasitic chemotherapy
PLoS Negl Trop Dis, 2022, 16(10)
Akito Koike, Katia Cailliau, Jerome Vicogne, Frank Becker, Peter Sennhenn, Colette Dissous, Stefan Hannus, Klaus Brehm
In vitro screening of kinase inhibitors on Echinococcus multilocularis
29th annual meeting of German Society for Parasitology, Bonn, March 15–17, 2021
Tillmann Michels, Antonio Sorrentino, Ayse Nur Menevse, Stefan Bissinger, Peter Sennhenn, Valentina Volpin, Sabrina Genssler Hannes Loferer, Christian Kohler, Rainer Spang, Michael Rheli, Christian Schmidl, Marco Breinig, Michael Boutros, Sebastian Meier-Ewert, Apollon Papadimitriou, Philipp Beckhove and Nisit Khandelwal
Salt-inducible kinase 3 facilitates tumor cell resistance against cytotoxic T cell attack by shifting TNF signaling from apoptosis to survival.
AACR Virtual Annual Meeting, 2020
Trebosc V., Gartenmann S., Royet K., Manfredi P., Tötzl M., Schellhorn B., Pieren M., Tigges M., Lociuro S., Sennhenn P., Gitzinger M., Bumann D., Kemmer C.
A novel genome editing platform for drug resistant Acinetobacter baumannii revealed an AdeR-unrelated tigecycline resistance mechanism.
Antimicrobial Agents and Chemotherapy, 2016, 60, 7263–7271
Schellhorn B., Kemmer C., Lucchini V., Gartenmann S., Trebosc V., Deroose F., Sennhenn P., Lociuro S., Tigges M., Gitzinger M., Pieren M.
Identification of VanR inhibitors re-sensitising vancomycin-resistant enterococci (VRE) towards glycopeptide antibiotics.
26th ECCMID Congress, Amsterdam, Netherlands, April 9–12, 2016
Conrad M., Schick J., Proneth B., Sennhenn P.
Tissue protection by non-apoptotic cell death inhibitors.
BioVaria, München, Germany, May 11, 2015
Chellat M., Raguz L., Sephton M., Züger P., Brand M., Schneider P., Tigges M., Gitzinger M., Sennhenn P., Pieren M., Levi A., Schellhorn B., Gygaxc D., Spiesc P., Riedl R.
Tackling Antibiotic Resistance by Transcription Repressor Inhibitory Compounds
Molecules for the Life Sciences, Swiss Chemical Society ILMAC-FH-Award 2013
Backes A., Sennhenn P., Müller G.
Design principles of kinase inhibitors.
In Protein Kinase Targets; Eds. Müller G., Klebl B.; VCH-Wiley: Weinheim, Germany, 2011
Müller G., Sennhenn P., Woodcock T., Neumann L.
The retro-design concept for novel kinase inhibitors.
IDrugs, 2010, 13, 457–466
Sennhenn P., Woodcock T., Müller G., Neumann L.
Novel Generation Kinase Inhibitors: Deep Pocket Binders by Fragment-Based Design
Frontiers in Medicinal Chemistry, Barcelona, Spain, 2009
Sennhenn P.
Ferroptosis, a Novel Druggable Cell Death Pathway: From Primary Screening Hit to Clinical Candidate
SAGIM Meeting, San Diego, CA, USA, April 12, 2019
Sennhenn P.
Long-Residence Time Kinase Inhibitors: Deep Pocket Binders by Fragment-Based Design
Fragment-Based Drug Design, Tokyo, Japan, Feb. 07, 2011
Sennhenn P.
Medicinal Chemistry: A Rule-Based Science?
9th Swiss Course on Medicinal Chemistry, Leysin, Switzerland, Oct. 12, 2010.
Sennhenn P.
Long Residence Time Kinase Inhibitors: Binding Kinetics in Fragment-Based Drug Design
Chemistry fro Preventing & Combating Disease, ACS National Meeting, Boston, MA, USA, Aug. 23, 2010.
Sennhenn P.
Post RO5 Optimization Parameters: Design Principles of Protein Kinase Inhibitors
Training Course at Screening, MedChem and ADMET Europe, Berlin, Germany, Feb. 26, 2009.
Sennhenn P.
Kinase Inhibitors with Tailored Binding Kinetics by Fragment-Based Design
Screening, MedChem and ADMET Europe, Berlin, Germany, Feb. 25, 2009.
Sennhenn P.
Fragment-Based Lead Discovery: a Viable Alternative to HTS?
Ringberg Meeting 2009: Academia Meets Industry, Ringberg, Germany, Jan. 08, 2009.
Sennhenn P.
Fragment-Based Lead Generation for Novel Kinase Inhibitors
Small Molecules, Antibodies and Natural Products: Multiple Faces of Medicinal Chemistry,
Leuven, Belgium, Noc. 07, 2008.
Sennhenn P.
Design Principles of Protein Kinase Inhibitors
Pre-Workshop at CHI 6th Annual Discovery on Target, Boston, MA, USA, Oct. 20., 2008.
Sennhenn P.
The Choice of the Aurora Enzyme is an Important Determinant in the Ligand Finding Process
Cell Based Assays, München, Germany May 21, 2008.
Sennhenn P.
The privileged structure concept applied to protein kinase Inhibitors
GTCbio’s 3rd Annual Conference on Protein Kinases in Drug Discovery,
San Diego, CA, USA, May 05, 2008.
Sennhenn P.
Selectivity of kinase inhibitors: From PknG to Aurora
GTCbio’s 2nd Annual Conference on Protein Kinases in Drug Discovery,
Boston, MA, USA, May 31, 2007.
Sennhenn P.
Aurora kinase inhibitors: Lead structure identification from the tetrahydrobenzo[b]thiophene class
Minisymposium: Drug Discovey and Design, AACR Annual Meeting,
Los Angeles, CA, USA, April 17, 2007.
In all phases of drug discovery, transMedChem leverages a well-established international expert network and AI-integrated tools to accelerate compound design and optimization, master complex challenges, and deliver the most efficient, cost-effective, and time-saving solutions for your project.
Available for strategic consulting and operational medicinal chemistry program execution
Based in Munich and Heidelberg, transMedChem maintains frequent on-site presence on the US West Coast and in the Boston biotech hub. Ready availability across Europe and Switzerland is complemented by full flexibility regarding time zones.
Peter Sennhenn, PhD
sennhenn@transMedChem.com
Looking forward to exploring a potential collaboration
